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Objectives: To investigate the association of comorbidities with mobility limitation and func-
tional disability in patients with rheumatoid arthritis and to identify which comorbidity
indicator is the most appropriate to determine this association.
Methods: Sixty rheumatoid arthritis patients were enrolled in a cross-sectional study for
a  period of 11 months. Comorbidities were assessed using three indicators: (i) the total
number of comorbidities; (ii) the Charlson comorbidity index; and (iii) the functional comor-
bidity index. Disease activity was assessed using the Disease Activity Score 28. Functional
capacity was measured using the Health Assessment Questionnaire, and mobility was mea-
sured using Timed Up and Go Test and Five-Times-Sit-to-Stand Test. Statistical analysis was
performed using a stepwise log-linear multiple regression with a signiﬁcance level of 5%.
Results: In the ﬁnal model, only comorbidity was associated with mobility limitation. The
functional comorbidity index score explained 19.1% of the variability of the Five-Times-Sit-
to-Stand Test (coefﬁcient of determination [R2] = 0.191) and 19.5% of the Timed Up and Go
Test variability (R2 = 0.195). With regard to functional disability, the associated factors were
comorbidity and disease activity, which together explained 32.9% of the variability of the
Health Assessment Questionnaire score (adjusted R2 = 0.329).
Conclusion: Comorbidities were associated with mobility limitation and functional disability
in  rheumatoid arthritis patients. The functional comorbidity index proved to be an appro-priate comorbidity indicator to determine this association.
© 2015 Elsevier Editora Ltda. All rights reserved.
∗ Corresponding author.
E-mail: wanessavmarques@yahoo.com.br (W.V. Marques).
http://dx.doi.org/10.1016/j.rbre.2015.07.009
2255-5021/© 2015 Elsevier Editora Ltda. All rights reserved.
r e v b r a s r e u m a t o l . 2 0 1 6;5  6(1):14–21 15
Inﬂuência  das  comorbidades  na  capacidade  funcional  de  pacientes
com  artrite  reumatoide
Palavras-chave:
Artrite reumatoide
Comorbidades
Capacidade funcional
Mobilidade
r  e  s  u  m  o
Objetivos: Investigar a associac¸ão das comorbidades com a limitac¸ão da mobilidade e com
a  incapacidade funcional em pacientes com artrite reumatoide, bem como identiﬁcar o
indicador de comorbidade mais apropriado para determinar essa associac¸ão.
Métodos: Em um estudo transversal foram incluídos 60 pacientes com artrite reumatoide
por  um período de 11 meses. Comorbidades foram avaliadas por meio de três indicadores:
(i)  número total de comorbidades; (ii) índice de comorbidade de Charlson; e (iii) índice de
comorbidade funcional. A atividade da doenc¸a foi avaliada pelo Índice de Atividade da
Doenc¸a  28. A capacidade funcional foi mensurada pelo Questionário de Avaliac¸ão da Saúde,
e  a mobilidade foi mensurada pelos testes senta-levanta da cadeira cinco vezes e timed get up
and  go.  A análise estatística foi realizada através de regressão múltipla log-linear Stepwise
com nível de signiﬁcância de 5%.
Resultados: No modelo ﬁnal, apenas o fator comorbidades esteve associado à mobilidade.
O  escore no índice de comorbidade funcional explicou 19,1% da variabilidade do teste
senta-levanta da cadeira cinco vezes (coeﬁciente de determinac¸ão [R2] = 0,191) e 19,5% da
variabilidade do timed get up and go (R2 = 0,195). Em relac¸ão à incapacidade funcional, os
fatores associados foram o fator comorbidades e a atividade da doenc¸a que em conjunto
explicaram 32,9% da variabilidade do escore do Questionário de Avaliac¸ão da Saúde (R2
ajustado = 0,329).
Conclusão: As comorbidades estão associadas com a limitac¸ão da mobilidade e a incapaci-
dade funcional em pacientes com artrite reumatoide. O índice de comorbidade funcional
demonstrou ser um indicador de comorbidade apropriado para determinar essa associac¸ão.
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dntroduction
heumatoid arthritis (RA) is a chronic, progressive, systemic
nﬂammatory disease which mainly affects the synovial mem-
rane of joints, which may cause general impairment in
unctional status of patients.1
The study of functional disability and associated factors in
A is relevant, since the functional status is related to other
linical outcomes in this population, such as mortality,2,3 loss
f work capacity,4,5 and use of health resources.6,7
There is increasing evidence pointing to the effect of the
omorbidity factor in functional disability in patients with RA.
adner et al.8,9 demonstrated the negative impact of comor-
idities in all areas of functional capacity, regardless of the
evel of disease activity. Michaud et al.,10 in a longitudinal
tudy, showed that age over 65 years and presence of comor-
idities were the main predictors of functional capacity loss in
A and that these factors not associated with the treatment of
A had the greatest effect in score progression, as measured by
he Health Assessment Questionnaire (HAQ), in comparison
ith the effect of the treatment with biological agents.
The study of Norton et al.11 showed a considerable preva-
ence of comorbidities at the time of diagnosis of RA and that
t increases over the course of the disease. After a 15-year
ollow-up, 81% of RA patients presented comorbidities and, in
ddition, presence of comorbidities was associated with mor-
11ality and loss of functional capacity in these patients. In an
1-year longitudinal study, Van den Hoek et al.12 observed that
omatic comorbidities and depression were associated with
ecreased functional capacity.©  2015 Elsevier Editora Ltda. Todos os direitos reservados.
The published literature reveals that comorbidities are
common conditions in this population, and on average each
patient with RA has 1.6 comorbidities; and this number
increases with age.13,14 In this sense, there has been a growing
interest from researchers in studying comorbidities and their
impact on different clinical outcomes in RA, such as hospital-
ization, mortality, functional capacity and medical costs.13–15
Comorbidity is deﬁned as a disease or medical condi-
tion that coexists with the disease of interest, identiﬁed,
in this case as RA.13 There are several ways to assess
comorbidities.13,15 The assessment of the impact of comor-
bidities in different clinical outcomes in patients with RA is
usually performed through a simple counting of the num-
ber of existing comorbidities from a speciﬁc list established
by researchers.15 Using such an approach, each condition is
equally scored, irrespective of its weight.15
Another way of measuring comorbidities involves the use
of validated comorbidity indexes for predicting a certain clin-
ical outcome.13 Most of comorbidity indexes are designed to
determine mortality, which is the case of Charlson comorbid-
ity index (CCI)16 and Kaplan–Feinstein index.17 CCI has been
developed by Charlson et al.,16 and contains a list of 19 condi-
tions, each of them having a weight according to its one-year
risk of death. There is also a comorbidity index speciﬁcally
developed to predict functionality, the functional comorbidity
index (FCI).18 FCI was developed by Groll et al.18 using a North-
American population affected mainly by orthopedic problems
and that used the Quality of Life Questionnaire (SF-36) to
quantify the subjects’ functional capacity.
Studies pointing to an association between comorbidi-
ties and functional disability8–12 evaluated the functionality
 t o l .16  r e v b r a s r e u m a
through the Health Assessment Questionnaire (HAQ) and/or
by the physical domain component of the Quality of Life Ques-
tionnaire (SF-36); these tools were developed to assess the
functional capacity of patients in activities of daily living.
None of these studies has added mobility tests in the assess-
ment of functionality. Thus, the mentioned studies8–12 did not
analyze the association of comorbidities with mobility limita-
tion in patients with RA.
The purpose of this study was to investigate the association
of comorbidities, measured by three indicators of comorbidity
(total number of comorbidities, CCI and FCI) with mobility lim-
itation and functional disability in patients with RA, as well as
to identify which indicator of comorbidity is most appropriate
to determine this association.
Methods
Study  design  and  participants
A cross-sectional study including patients with RA was carried
out to evaluate the association of comorbidities with mobility
limitation and functional disability in these individuals.
Sixty patients participated in the study and were recruited
from the Rheumatology Outpatient Clinic of Hospital das
Clínicas, Faculdade de Medicina, Universidade Federal de
Goiás (UFG) in the city of Goiânia, from September 13, 2012
to August 22, 2013.
At inclusion, all patients met  the American College of
Rheumatology (ACR 1987) criteria for RA.19 Those subjects
with hospitalization due to acute infection in the period of
six months prior to the interview and with presence of some
temporary disability making it impossible to carry out mobil-
ity tests (e.g., foot fracture) were excluded. The study was
approved by the Research Ethics Committee of the Hospital
das Clínicas (UFG) and all participants signed an informed
consent form.
Assessment  tools
At the time study enrollment, patients completed a stan-
dardized questionnaire, including details of: (i) demographic
factors such as age, gender and self-reported race; (ii) pres-
ence of a positive rheumatoid factor (RF); (iii) disease duration;
(iv) existing comorbidities; (v) history of falls in a 12-month
period preceding the interview; (vi) use of walking aids; (vii)
medications in use; (viii) lifestyle habits (i.e., smoking sta-
tus – current or former smoker, never smoked) and physical
activity practice. This questionnaire was supplemented with
information from participants’ medical records.
In this standardized questionnaire, comorbidities were
evaluated through a list of chronic diseases, according to those
covered by CCI16 and FCI.18 The presence of other chronic dis-
eases not included in these indexes but reported by patients
and conﬁrmed in their medical records was also registered.
From these collected data, comorbidities were measured by
three indicators: (i) total number of comorbidities (NCom); (ii)
CCI score; and (iii) FCI score.
CCI is composed of a list of 19 comorbidities, and each dis-
ease has a weight ranging from 1 to 6, established according 2 0 1 6;5 6(1):14–21
to its one-year risk of death.16 The score obtained in CCI is
assigned by summing all comorbidities present with their
respective weights, resulting in a number which can vary
from 0 to 33.16
FCI is a list of 18 comorbidities, with no difference in weight
among them.18 FCI score is obtained by summing all comor-
bidities, ranging from 0 to 18.18
In the “connective tissue diseases” item contemplated in
CCI, the tool considered as “comorbid condition” the pres-
ence of systemic lupus erythematosus, polymyositis, mixed
connective tissue disease and polymyalgia rheumatica, as
suggested by Charlson et al.16 On the other hand, in FCI, in
its “arthritis” item, only presence of osteoarthritis was con-
sidered.
Disease activity was assessed by the Disease Activity Score
based on 28 joints and on ESR value (DAS-28/ESR).20
To assess mobility limitation, the following tests were
applied: (i) Five-Times-Sit-to-Stand Test (STS)21 and (ii) Timed
Up and Go Test (TUG).22
STS test is used to evaluate muscle strength of lower limbs,
mobility and risk of falls.21,23,24 This test, measures the fastest
time to stand and sit ﬁve consecutive times with arms folded.
The longer the time spent to complete the test, the worse the
individual mobility.21
TUG test is used to identify patients at risk of falls and with
mobility restriction.22,25 To perform this test, the patient is
timed while they rise from an arm chair, walk at a comfortable
and safe pace to a line on the ﬂoor 3 m away, turn and walk
back to the chair and sit down again. The greater the time, the
worse the individual mobility.22
Functional disability was measured by the Health Assess-
ment Questionnaire (HAQ).26,27
Statistical  analysis
Continuous data are shown as mean (standard deviation [SD])
or median (interquartile range [IQR]), where appropriate, and
categorical data were shown as frequency (percentages).
A regression analysis using quasi-likelihood model,28 with
variance function proportional to the mean and logarithmic
link function, was carried out, in order to investigate the
association of indicators of comorbidity (NCom, CCI and FCI)
with mobility limitation (STS and TUG) and functional disabil-
ity (HAQ). To monitor the effect of confounding variables, a
linear regression model using stepwise regression was con-
structed. The potential confounding variables chosen were:
age, gender, disease duration, physical activity, positive RF
test, DAS-28/ESR score.
The ﬁnal model of multiple regression analysis for the
dependent variables STS, TUG and HAQ was called stepwise
log-linear regression.
The comparison between comorbidity indicators, with the
aim to establish the most appropriate tool to determine the
association of comorbidities with mobility limitation and
functional disability in patients with RA, was performed by
2comparing the coefﬁcients of determination (R ) of adjusted
models against each indicator.29
The level of statistical signiﬁcance was 5%. The software R
version 3.0.1 was used in data analysis.
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Table 1 – Characteristics of participants.
Characteristics Values
Demographics
Age, mean (SD) (min–max), years 59 (9.1) (43–80)
Women, n (%) 53 (88.3%)
Self-reported race, n (%)
Caucasian 26 (43.3%)
African 11 (18.3%)
Brown 23 (38.3%)
Positive RF, n (%) 43  (71.7%)
Disease duration, mean (SD) (min–max), years 11.5 (8.9) (0.4–30)
History of falls, n (%) 16  (26.7%)
Use of walking aids, n (%) 8 (13.3%)
Smokers or former smokers, n (%) 37 (61.7%)
Practitioners of physical activity, n (%) 10 (16.7%)
Evaluation of comorbidities
NCom score, mean (SD) (min–max) 3.6 (2.1) (0–8)
CCI score, mean (SD) (min–max) 0.25 (0.51) (0–2)
FCI score, mean (SD) (min–max) 2.0 (1.5) (0–5)
Disease activity assessment
ESR, median (IQR), mm/hour 22.5 (10.5–34.5)
DAS-28/ESR, mean (SD) (min–max) 3.7 (1.4) (0.5–6.8)
Mobility assessment
STS, median (IQR), seconds 12.5  (10.5–20.4)
TUG, median (IQR), seconds 12.8  (10.9–16.3)
Assessment of functional capacity
HAQ score, mean (SD) (min–max) 1.07 (0.76) (0–3)
SD, standard deviation; IQR, interquartile range; RF, rheumatoid
factor; NCom, total number of comorbidities; CCI, Charlson comor-
bidity index; FCI, functional comorbidity index; ESR, erythrocyte
sedimentation rate; DAS-28/ESR, Disease Activity Score based on
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some of the variability in STS and TUG test performance.28 joints and on ESR value; STS, Five-Times-Sit-to-Stand Test; TUG,
Timed Up and Go Test; HAQ, Health Assessment Questionnaire.
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ixty patients participated in the study. Patient characteristics
re summarized in Table 1.
Table 2 depicts the comorbidities that make up CCI and FCI,
s well as the number of patients affected by each comorbid-
ty present in these indexes. The prevalence of comorbidities
iven by CCI was 21.7%, i.e., 13 patients had at least one
omorbidity, according to this indicator. In the other hand, the
valuation by FCI showed that 49 (81.7%) patients had at least
ne comorbidity.
Patients had other comorbidities, besides those shown
n Table 2, such as ﬁbromyalgia, anemia, epilepsy, hypothy-
oidism, secondary Sjögren syndrome and cardiac arrhyth-
ias. Thus, the prevalence of comorbidities given by NCom
as 90%, i.e., 54 patients had at least one comorbidity.
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The independent factors that signiﬁcantly explain part
of the variability of STS in the univariate model were: age
(coefﬁcient of determination [R2] = 0.074; p = 0.023), male gen-
der (R2 = 0.058; p = 0.049), disease duration (R2 = 0.056; p = 0.042),
NCom score (R2 = 0.121; p = 0.005) and FCI score (R2 = 0.191,
p < 0.001). The independent factors associated with variabil-
ity of TUG in the univariate model were: age (R2 = 0.063;
p = 0.052), NCom score (R2 = 0.144, p = 0.005) and FCI score
(R2 = 0.195; p = 0.001). On the other hand, the independent
factors associated with variability of HAQ in the univari-
ate model were: disease duration (R2 = 0.047; p = 0.040), NCom
score (R2 = 0.077; p = 0.012), FCI score (R2 = 0.178, p < 0.001) and
DAS-28/ESR (R2 = 0.244, p < 0.001) (Table 3).
The log-linear regression curves of the main independent
factors associated with variability of mobility (STS and TUG)
and functional capacity (HAQ) are shown in Fig. 1.
In the ﬁnal model of log-linear regression using stepwise
regression with respect to factors associated with mobility
limitation (STS and TUG), only the “comorbidities” factor, eval-
uated by FCI, was signiﬁcant (Table 4). The exponent values
of beta coefﬁcient (expˇ) for the association between FCI and
STS was 1.128 (95% conﬁdence interval [95% CI] 1.062–1.201;
p < 0.001); and for TUG was 1172 (95% CI 1.073–1.285; p = 0.001)
(Table 4).
As to factors associated with functional disability (HAQ) in
the ﬁnal model, the following variables were signiﬁcant: dis-
ease activity, measured by DAS-28/ESR (exp  ˇ = 1.279, 95% CI
1.132–1.451; p < 0.001) and comorbidities as assessed by FCI
(expˇ = 1.167, 95% CI 1.054–1.290; p = 0.005) (Table 4). FCI and
DAS-28/ESR factors were signiﬁcant to explain, together, 32.9%
of the variability of HAQ score (adjusted R2 = 0.329) (Table 4).
Comparison  among  comorbidity  indicators
FCI proved to be the most appropriate comorbidity indicator
to determine the association of comorbidities with mobility
limitation (STS and TUG) and functional disability (HAQ) in
patients with RA, according to values of the coefﬁcients of
determination (R2) of comorbidity indicators (NCom, CCI and
FCI) (Table 3).
The R2 value for an association between FCI and STS was
0.191; for TUG was 0.195; and for HAQ was 0.178. On the other
hand, R2 between NCom and STS was 0.121; for TUG,  R2 = 0.144;
and for HAQ, R2 = 0.077. And the R2 value between CCI and STS
was 0.021; for TUG, R2 = 0.000; and for HAQ, R2 = 0.000 (Table 3).
Discussion
This study demonstrated the association of comorbidities
with mobility limitation and functional disability in patients
with RA and indicated FCI as an appropriate comorbidity index
in determining this association.
In this study, the multivariate analysis of factors asso-
ciated with mobility limitation showed that only the factor
“comorbidities”, assessed by FCI score, contributed to explainFCI explained 19.1% of the variability of STS and 19.5% of
the variability of TUG. The percentage of variability of HAQ
score explained by the variables used in the ﬁnal model
18  r e v b r a s r e u m a t o l .
Table 2 – Comorbidities that compose the Charlson
comorbidity index and the functional comorbidity index
and number of affected patients.
Comorbidities n
Osteoporosis 28
Arthritis (osteoarthritis)b 27
Visual deﬁcits (cataract, glaucoma, macular
degeneration)b
17
Obesity and/or BMI >30 kg/m2b 12
Upper gastrointestinal tract disease (ulcer, hernia,
reﬂux)a,b
11
Diabetes mellitus type 2a,b 9
Depressionb 5
Anxiety or panic syndromeb 3
Auditory deﬁcits (difﬁculty hearing, even
with hearing aids)b
3
Congestive heart failurea,b 1
Peripheral vascular diseasea,b 1
Cerebrovascular diseasea,b 1
Chronic obstructive pulmonary diseasea,b 1
Asthmab 1
Neurological disease (Parkinson’s disease)b 1
Connective tissue diseasea 0
Liver disease (mild, moderate or severe)a 0
Anginab/myocardial infarctiona,b 0
Degenerative disk disease (spinal stenosis, or severe
chronic low back pain)b
0
Dementiaa 0
Hemiplegiaa 0
Moderate or severe kidney diseasea 0
Non-metastatic solid tumora 0
Leukemiaa 0
Lymphomaa 0
Solid metastatic tumora 0
AIDSa 0
CCI, Charlson comorbidity index; FCI, functional comorbidity
index; BMI, body mass index; AIDS, acquired immunodeﬁciency
syndrome.
a Comorbidity present in CCI.
comorbidities that make up CCI are not those most oftenb Comorbidity present in FCI.
was 32.9%; and “disease activity”, measured by DAS-28/ESR,
was the main variable responsible for explaining part of this
variability, followed by the factor “comorbidities”, assessed
by FCI. In the ﬁnal model – after FCI and DAS-28/ESR had
explained part of the variability of HAQ score, and after FCI
had explained part of the variability of STS and TUG – the
remaining analyzed variables did not contribute signiﬁcantly
to explain the mobility limitation and functional disability
observed, showing the importance of the factor “comorbidi-
ties” in the face of other variables, such as age, gender, disease
duration, physical activity and a positive RF.
Functional disability in RA is characterized by its multi-
dimensionality, being associated with multiple factors, aside
the factor “comorbidities”,8–12 such as pain,30,31 reduced joint
mobility,30 articular cartilage destruction,32 decreased muscle
strength,31 disease duration33 and disease activity.31
The association of comorbidities with functional disability
in patients with RA has been shown in some studies,8–12 in
which the authors assessed the functional capacity of patients
through activities of daily living questionnaires (HAQ and/or
SF-36). 2 0 1 6;5 6(1):14–21
To our knowledge, this is the ﬁrst study on RA patients
to determine the association of comorbidities with mobility
limitation measured by timed tests (STS and TUG).
The fact that RA is responsible for a general impairment
in terms of functional status of patients, causing impairment
in activities of daily living, muscle strength and mobility and
increasing the risk of falls, emphasizes the importance of
mobility studies in this population.31,34,35
The risk of falls can be evaluated through the time spent
to perform STS and TUG tests24,25,36 and, in parallel, studies
have shown a worse performance on these tests in patients
with RA, when compared to the population without RA.37,38
Böhler et al.36 showed that disease activity and functional
disability (HAQ) in patients with RA correlated with worse
performance in STS and TUG tests; but the authors did not
evaluate the association of comorbidities with risk of falls.
Jamison et al.39 demonstrated that patients with RA with a his-
tory of falls exhibited a higher number of comorbidities than
those without such history, drawing attention to the associa-
tion between comorbidities and the occurrence of falls in this
population. As occurred in the study by Böhler et al.,36 Jamison
et al.39 have not studied the association of comorbidities with
performance tests for fall risk assessment (STS and TUG).
The study of factors associated with risk of falls in patients
with RA is a relevant task, since the risk of falls in these
patients is increased.34–37,39,40 Falls, in turn, are related to the
occurrence of fractures; and this contingency has the effect
of compromising the functionality, worsening the prognosis
of rheumatologic diseases.35 Also noteworthy is an increased
prevalence of osteoporosis in patients with RA.11,13,15 In our
study, 28 patients (47%) had osteoporosis, and this is a comor-
bidity which increases fracture risk.37,41
In the present study, we evaluated the association of
comorbidities with mobility limitation and functional disabil-
ity in patients with RA by computing the total number of
comorbidities (NCom) and through the score obtained with
the use of CCI and FCI.
FCI proved to be the most appropriate comorbidity indica-
tor in determining this association, when compared to NCom
and CCI in our sample. The association of comorbidities evalu-
ated by FCI was stronger versus that measured by NCom. This
result was expected, since FCI has been specially developed
as a tool to predict functionality.18 This ﬁnding is highlighted
by the fact that RA patients studied often presented with
comorbidities present in FCI, these being conditions clearly
associated with functional impairment.18
On the other hand, the lack of association of those comor-
bidities assessed by CCI in our sample, notwithstanding the
demonstration of this relationship with the use of CCI in other
studies,8,9,11 can be explained in two ways. First, we  must con-
sider that CCI was primarily developed as an instrument to
predict mortality.16 And secondly, we did not ﬁnd in our sam-
ple a reasonable amount of comorbidities pertaining to the
calculation of ICC, and this fact may have hampered the abil-
ity of this index in predicting functionality in our patients.
Perhaps this scenario would require a larger sample, as thefound in outpatients with RA.8,9,11
Our study has some limitations with respect to the form of
identiﬁcation of comorbidities, which was based on patients
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Table 3 – Analysis of independent factors associated with mobility limitation (Five-Times-Sit-to-Stand Test and Timed
Up and Go Test) and functional disability (Health Assessment Questionnaire).
Independent variables Dependent variables
STS TUG HAQ
Age, years R2 0.074a 0.063a 0.002
Male gender R2 0.058a 0.010 0.000
Positive RF R2 0.000 0.000 0.000
Disease duration, years R2 0.056a 0.020 0.047a
Physical activity R2 0.000 0.003 0.013
NCom score R2 0.121b 0.144b 0.077b
CCI score R2 0.021 0.000 0.000
FCI score R2 0.191b 0.195b 0.178b
DAS-28/ESR R2 0.033 0.056 0.244b
STS, Five-Times-Sit-to-Stand Test; TUG, Timed Up and Go Test; HAQ, Health Assessment Questionnaire; R2, coefﬁcient of determination; RF,
rheumatoid factor; NCom, total number of comorbidities; CCI, Charlson comorbidity index; FCI, functional comorbidity index; DAS-28/ESR,
Disease Activity Score based on 28 joints and on ESR value.
Univariate log-linear regressions.
a Signiﬁcant p ≤ 0.05.
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Table 4 – Impact of comorbidity (functional comorbidity index) and disease activity (Disease Activity Score based
on 28 joints and on ESR value) in mobility (Five-Times-Sit-to-Stand Test and Timed Up and Go Test) and functional
capacity (Health Assessment Questionnaire).
Dependent variables Independent variables exp(ˇ) 95% CI p Adjusted R2
STS FCI 1.128 1.062–1.201 <0.001 0.191
TUG FCI 1.172 1.073–1.285 0.001 0.195
HAQ FCI 1.167 1.054–1.290 0.005 0.329
DAS-28/ESR 1.279 1.132–1.451 <0.001
STS, Five-Times-Sit-to-Stand Test; TUG, Timed Up and Go Test; HAQ, Health Assessment Questionnaire; exp(ˇ), exponential of beta coefﬁcient;
95% CI, conﬁdence interval of 95%; R2, coefﬁcient of determination; FCI, functional comorbidity index; DAS-28/ESR, Disease Activity Score based
r
1
1
1
1
1
1
1
1
1
1
2on 28 joints and on ESR value.
Multivariate log-linear regression model using stepwise regression.
functionality in patients with RA; with this, we  can obtain
more suitable criteria, when establishing the comorbidities
associated with functional status of this population.
This study has relevance for pointing out the effect of
comorbidities on limiting the mobility and, hence, on increas-
ing the risk of falls in patients with RA; it must be taken into
account that the tests used (STS and TUG) are recommended
in the fall risk assessment. In addition, the study also draws
attention to the use of FCI as an alternative tool to evaluate
the impact of comorbidities on functionality of patients with
RA.
In conclusion, the comorbidities in patients with RA are
associated with mobility limitation and functional disability;
and the indicator FCI is an appropriate comorbidity index in
the determination of this association.
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